- After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaborationAfter signing a deal worth up to $486 million with Italian biopharma Chiesi to develop its pulmonary arterial hypertension (PAH) candidate seralutinib in 2024, Gossamer Bio has ended the collaborat…Fierce Biotech · 1d ago↗ source
- Legend Biotech CEO abruptly steps down without permanent replacementIn a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.Fierce Biotech · 1d ago↗ source
- From confidence to capital: Positioning biotech for the next growth cycle<p>How can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026.</p>